{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:55Z","timestamp":1772166355823,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01702-6","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:06:25Z","timestamp":1748487985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Elnaz","family":"Salari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negar","family":"Ajabi Ardehjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasra","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-8331","authenticated-orcid":false,"given":"Ashraf","family":"Moini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"3","key":"1702_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.fertnstert.2012.05.042","volume":"98","author":"K Jayaprakasan","year":"2012","unstructured":"Jayaprakasan K, Chan Y, Islam R, Haoula Z, Hopkisson J, Coomarasamy A, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril. 2012;98(3):657\u201363.","journal-title":"Fertil Steril"},{"issue":"6","key":"1702_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","volume":"44","author":"A Golan","year":"1989","unstructured":"Golan A, Ron-El R, Herman A, Soffer Y. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44(6):430\u201340.","journal-title":"Obstet Gynecol Surv"},{"key":"1702_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-7-56","volume":"7","author":"J Haas","year":"2014","unstructured":"Haas J, Yinon Y, Meridor K, Orvieto R. Pregnancy outcome in severe OHSS patients following ascitic\/plerural fluid drainage. J Ovarian Res. 2014;7:1\u20134.","journal-title":"J Ovarian Res"},{"key":"1702_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-7-54","volume":"7","author":"K Nouri","year":"2014","unstructured":"Nouri K, Haslinger P, Szabo L, Sator M, Schreiber M, Schneeberger C, et al. Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)\u2014a retrospective case\u2013control study. J Ovarian Res. 2014;7:1\u20137.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1702_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0015-0282(16)57353-1","volume":"63","author":"MP Goldsman","year":"1995","unstructured":"Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63(2):268\u201372.","journal-title":"Fertil Steril"},{"key":"1702_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10815-010-9387-6","volume":"27","author":"CO Nastri","year":"2010","unstructured":"Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010;27:121\u20138.","journal-title":"J Assist Reprod Genet"},{"key":"1702_CR7","doi-asserted-by":"publisher","first-page":"615957","DOI":"10.3389\/fendo.2020.615957","volume":"11","author":"B Sun","year":"2021","unstructured":"Sun B, Ma Y, Li L, Hu L, Wang F, Zhang Y, et al. Factors associated with ovarian hyperstimulation syndrome (OHSS) severity in women with polycystic ovary syndrome undergoing IVF\/ICSI. Front Endocrinol. 2021;11:615957.","journal-title":"Front Endocrinol"},{"issue":"9","key":"1702_CR8","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/humrep\/dew149","volume":"31","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Nelson S, Devroey P, Coddington C, Schwartz L, Gordon K, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016;31(9):1997\u20132004.","journal-title":"Hum Reprod"},{"issue":"3","key":"1702_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.fertnstert.2020.04.004","volume":"114","author":"DA Schirmer III","year":"2020","unstructured":"Schirmer DA III, Kulkarni AD, Zhang Y, Kawwass JF, Boulet SL, Kissin DM. Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes. Fertil Steril. 2020;114(3):567\u201378.","journal-title":"Fertil Steril"},{"issue":"11","key":"1702_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1701-2163(16)35085-X","volume":"33","author":"D Shmorgun","year":"2011","unstructured":"Shmorgun D, Claman P, Gysler M, Hemmings R, Cheung AP, Goodrow GJ, et al. The diagnosis and management of ovarian hyperstimulation syndrome. J Obstet Gynecol Can. 2011;33(11):1156\u201362.","journal-title":"J Obstet Gynecol Can"},{"key":"1702_CR11","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0049-3848(17)30070-1","volume":"151","author":"SM Nelson","year":"2017","unstructured":"Nelson SM. Prevention and management of ovarian hyperstimulation syndrome. Thromb Res. 2017;151:S61\u20134.","journal-title":"Thromb Res"},{"key":"1702_CR12","doi-asserted-by":"publisher","first-page":"104314","DOI":"10.1016\/j.jri.2024.104314","volume":"165","author":"H-M Zhang","year":"2024","unstructured":"Zhang H-M, Yao B, Li L, Guo S-S, Deng H-Y, Ren Y-P. Causal relationship between OHSS and immune cells: A Mendelian randomization study. J Reprod Immunol. 2024;165:104314.","journal-title":"J Reprod Immunol"},{"issue":"1","key":"1702_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2265.1989.tb03729.x","volume":"30","author":"J Eden","year":"1989","unstructured":"Eden J, Place J, Carter G, Alaghband-Zadeh J, Pawson M. Is the polycystic ovary a cause of infertility in the ovulatory woman? Clin Endocrinol. 1989;30(1):77\u201382.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"1702_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/oxfordjournals.humrep.a019031","volume":"11","author":"R Homburg","year":"1996","unstructured":"Homburg R. Polycystic ovary syndrome\u2014from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. 1996;11(1):29\u201339.","journal-title":"Hum Reprod"},{"issue":"1","key":"1702_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rbmo.2011.09.017","volume":"24","author":"J Pundir","year":"2012","unstructured":"Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online. 2012;24(1):6\u201322.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"1702_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.fertnstert.2013.11.005","volume":"101","author":"VM Leitao","year":"2014","unstructured":"Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2014;101(3):664\u201375. e7.","journal-title":"Fertil Steril"},{"issue":"1","key":"1702_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12958-023-01113-6","volume":"21","author":"S Palomba","year":"2023","unstructured":"Palomba S, Costanzi F, Nelson SM, Caserta D, Humaidan P. Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence. Reproductive Biology Endocrinol. 2023;21(1):67.","journal-title":"Reproductive Biology Endocrinol"},{"issue":"18","key":"1702_CR18","doi-asserted-by":"publisher","first-page":"14185","DOI":"10.3390\/ijms241814185","volume":"24","author":"S Palomba","year":"2023","unstructured":"Palomba S, Costanzi F, Nelson SM, Besharat A, Caserta D, Humaidan P. Beyond the umbrella: a systematic review of the interventions for the prevention of and reduction in the incidence and severity of ovarian hyperstimulation syndrome in patients who undergo in vitro fertilization treatments. Int J Mol Sci. 2023;24(18):14185.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1702_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/humupd\/dmn008","volume":"14","author":"SR Soares","year":"2008","unstructured":"Soares SR, G\u00f3mez R, Sim\u00f3n C, Garc\u00eda-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14(4):321\u201333.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"1702_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ajog.2020.09.007","volume":"224","author":"KF Huybrechts","year":"2021","unstructured":"Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):290. e1-. e22.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1702_CR21","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.3390\/ijms21072504","volume":"21","author":"RA Rahman","year":"2020","unstructured":"Rahman RA, Murthi P, Singh H, Gurungsinghe S, Leaw B, Mockler JC, et al. Hydroxychloroquine mitigates the production of 8-isoprostane and improves vascular dysfunction: implications for treating preeclampsia. Int J Mol Sci. 2020;21(7):2504.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1702_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/14767058.2017.1289511","volume":"31","author":"R Abd Rahman","year":"2018","unstructured":"Abd Rahman R, DeKoninck P, Murthi P, Wallace EM. Treatment of preeclampsia with hydroxychloroquine: a review. J Maternal-Fetal Neonatal Med. 2018;31(4):525\u20139.","journal-title":"J Maternal-Fetal Neonatal Med"},{"key":"1702_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","volume":"195","author":"M Torigoe","year":"2018","unstructured":"Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y. Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 Inhibition. Clin Immunol. 2018;195:1\u20137.","journal-title":"Clin Immunol"},{"issue":"9","key":"1702_CR24","doi-asserted-by":"publisher","first-page":"e0139226","DOI":"10.1371\/journal.pone.0139226","volume":"10","author":"AM Shukla","year":"2015","unstructured":"Shukla AM, Bose C, Karaduta OK, Apostolov EO, Kaushal GP, Fahmi T, et al. Impact of hydroxychloroquine on atherosclerosis and vascular stiffness in the presence of chronic kidney disease. PLoS ONE. 2015;10(9):e0139226.","journal-title":"PLoS ONE"},{"key":"1702_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0790-3","volume":"17","author":"A Virdis","year":"2015","unstructured":"Virdis A, Tani C, Duranti E, Vagnani S, Carli L, K\u00fchl AA, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Therapy. 2015;17:1\u20139.","journal-title":"Arthritis Res Therapy"},{"issue":"12","key":"1702_CR26","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1093\/humrep\/12.12.2629","volume":"12","author":"R Mathur","year":"1997","unstructured":"Mathur R, Jenkins J, Bansal A. The possible role of the immune system in the aetiopathogenesis of ovarian hyperstimulation syndrome. Hum Reprod (Oxford England). 1997;12(12):2629\u201334.","journal-title":"Hum Reprod (Oxford England)"},{"key":"1702_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-020-00624-9","volume":"13","author":"B Farkas","year":"2020","unstructured":"Farkas B, Boldizsar F, Bohonyi N, Farkas N, Marczi S, Kovacs GL, et al. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS). J Ovarian Res. 2020;13:1\u20138.","journal-title":"J Ovarian Res"},{"issue":"7","key":"1702_CR28","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/oxfordjournals.humrep.a019404","volume":"11","author":"Y Abramov","year":"1996","unstructured":"Abramov Y, Schenker J, Lewin A, Friedler S, Nisman B, Barak V. Endocrinology: plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod. 1996;11(7):1381\u20136.","journal-title":"Hum Reprod"},{"key":"1702_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jsgi.2004.05.001","volume":"11","author":"R Orvieto","year":"2004","unstructured":"Orvieto R. Controlled ovarian hyperstimulation\u2014an inflammatory state. J Soc Gynecologic Investigation: JSGI. 2004;11:424\u20136.","journal-title":"J Soc Gynecologic Investigation: JSGI"},{"issue":"1","key":"1702_CR30","doi-asserted-by":"publisher","first-page":"10175","DOI":"10.1038\/s41598-022-14571-6","volume":"12","author":"R Wakiya","year":"2022","unstructured":"Wakiya R, Ueeda K, Nakashima S, Shimada H, Kameda T, Mansour MMF, et al. Effect of add-on hydroxychloroquine therapy on serum Proinflammatory cytokine levels in patients with systemic lupus erythematosus. Sci Rep. 2022;12(1):10175.","journal-title":"Sci Rep"},{"issue":"1","key":"1702_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/hiv.12171","volume":"16","author":"JP Routy","year":"2015","unstructured":"Routy JP, Angel J, Patel M, Kanagaratham C, Radzioch D, Kema I, et al. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16(1):48\u201356.","journal-title":"HIV Med"},{"key":"1702_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-021-00773-5","volume":"14","author":"S Yacoub","year":"2021","unstructured":"Yacoub S, Cadesky K, Casper RF. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series. J Ovarian Res. 2021;14:1\u20136.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1702_CR33","first-page":"157","volume":"9","author":"A Salmassi","year":"2015","unstructured":"Salmassi A, Mettler L, Hedderich J, Jonat W, Deenadayal A, Von Otte S, et al. Cut-off levels of anti-mullerian hormone for the prediction of ovarian response, in vitro fertilization outcome and ovarian hyperstimulation syndrome. Int J Fertility Steril. 2015;9(2):157.","journal-title":"Int J Fertility Steril"},{"issue":"1","key":"1702_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"REASPCW Group","year":"2004","unstructured":"Group REASPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137.","journal-title":"Hum Reprod"},{"issue":"1","key":"1702_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S1472-6483(10)60042-9","volume":"19","author":"A Golan","year":"2009","unstructured":"Golan A, Weissman A. A modern classification of OHSS. Reprod Biomed Online. 2009;19(1):28\u201332.","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"1702_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Statistics: J Appl Stat Pharm Ind. 2005;4(4):287\u201391.","journal-title":"Pharm Statistics: J Appl Stat Pharm Ind"},{"issue":"8","key":"1702_CR37","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1210\/jc.2007-0409","volume":"92","author":"C \u00c1lvarez","year":"2007","unstructured":"\u00c1lvarez C, Mart\u00ed-Bonmat\u00ed L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M, et al. Dopamine agonist Cabergoline reduces hemoconcentration and Ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metabolism. 2007;92(8):2931\u20137.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1702_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00001703-200306000-00007","volume":"15","author":"JA Garcia-Velasco","year":"2003","unstructured":"Garcia-Velasco JA, Pellicer A. New concepts in the Understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol. 2003;15(3):251\u20136.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1702_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-016-0237-8","volume":"9","author":"UM Fouda","year":"2016","unstructured":"Fouda UM, Sayed AM, Elshaer HS, Hammad BEM, Shaban MM, Elsetohy KA, et al. GnRH antagonist rescue protocol combined with Cabergoline versus Cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. J Ovarian Res. 2016;9:1\u20138.","journal-title":"J Ovarian Res"},{"issue":"5","key":"1702_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/humupd\/dmq006","volume":"16","author":"MA Youssef","year":"2010","unstructured":"Youssef MA, Van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010;16(5):459\u201366.","journal-title":"Hum Reprod Update"},{"key":"1702_CR41","doi-asserted-by":"crossref","unstructured":"Tang H, Mourad SM, Wang A, Zhai S-D, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Reviews. 2021;(4).","DOI":"10.1002\/14651858.CD008605.pub4"},{"issue":"04","key":"1702_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/2231-0770.165121","volume":"5","author":"N Kilic","year":"2015","unstructured":"Kilic N, \u00d6zdemir \u00d6, Ba\u015far HC, Demircan F, Ekmez F, Y\u00fccel O. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization\/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna J Med. 2015;5(04):123\u20137.","journal-title":"Avicenna J Med"},{"issue":"11","key":"1702_CR43","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/humrep\/16.11.2263","volume":"16","author":"E Papaleo","year":"2001","unstructured":"Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod. 2001;16(11):2263\u20136.","journal-title":"Hum Reprod"},{"issue":"10","key":"1702_CR44","first-page":"837","volume":"11","author":"A Torabizadeh","year":"2013","unstructured":"Torabizadeh A, Vahidroodsari F, Ghorbanpour Z. Comparison of albumin and Cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study. Iran J Reproductive Med. 2013;11(10):837.","journal-title":"Iran J Reproductive Med"},{"issue":"606","key":"1702_CR45","first-page":"982","volume":"38","author":"E Naghshineh","year":"2021","unstructured":"Naghshineh E, Khani B, Mesgari L. The efficiency of Gnrh antagonist (cetrotide) in comparison of Cabergoline in the prevention and treatment of ovarian hyperstimulation syndrome. J Isfahan Med School. 2021;38(606):982\u20138.","journal-title":"J Isfahan Med School"},{"issue":"1","key":"1702_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/01443615.2020.1870944","volume":"42","author":"UM Fouda","year":"2022","unstructured":"Fouda UM, Elshaer HS, Youssef GG, Hanafy A, Mehrem WM, Youssef MA, et al. Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study. J Obstet Gynaecol. 2022;42(1):122\u20136.","journal-title":"J Obstet Gynaecol"},{"key":"1702_CR47","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.biopha.2018.08.027","volume":"107","author":"H Ghasemnejad-Berenji","year":"2018","unstructured":"Ghasemnejad-Berenji H, Novin MG, Hajshafiha M, Nazarian H, Hashemi S, Ilkhanizadeh B, et al. Immunomodulatory effects of hydroxychloroquine on Th1\/Th2 balance in women with repeated implantation failure. Biomed Pharmacother. 2018;107:1277\u201385.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1702_CR48","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3899\/jrheum.170737","volume":"45","author":"J Yang","year":"2018","unstructured":"Yang J, Yang X, Yang J, Li M. Hydroxychloroquine inhibits the differentiation of Th17 cells in systemic lupus erythematosus. J Rhuematol. 2018;45(6):818\u201326.","journal-title":"J Rhuematol"},{"issue":"8","key":"1702_CR49","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/0961203312437270","volume":"21","author":"R Willis","year":"2012","unstructured":"Willis R, Seif A, McGwin G Jr, Martinez-Martinez L, Gonz\u00e1lez E, Dang N, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus. 2012;21(8):830\u20135.","journal-title":"Lupus"},{"issue":"11","key":"1702_CR50","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1002\/art.11304","volume":"48","author":"N Costedoat-Chalumeau","year":"2003","unstructured":"Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty\u2010three cases compared with a control group. Arthr Rhuem. 2003;48(11):3207\u201311.","journal-title":"Arthr Rhuem"},{"issue":"7","key":"1702_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/ard.55.7.486","volume":"55","author":"N Buchanan","year":"1996","unstructured":"Buchanan N, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes G. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis. 1996;55(7):486\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1702_CR52","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"ME Clowse","year":"2006","unstructured":"Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2006;54(11):3640\u20137.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"2","key":"1702_CR53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/art.38262","volume":"66","author":"WO Cooper","year":"2014","unstructured":"Cooper WO, Cheetham TC, Li DK, Stein CM, Callahan ST, Morgan TM, et al. Brief report: risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. Arthritis Rheumatol. 2014;66(2):444\u201350.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1702_CR54","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/jog.14561","volume":"47","author":"MS Beksac","year":"2021","unstructured":"Beksac MS, Donmez HG. Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug. J Obstet Gynecol Res. 2021;47(2):570\u20135.","journal-title":"J Obstet Gynecol Res"},{"key":"1702_CR55","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0049-3848(19)30366-4","volume":"181","author":"K Schreiber","year":"2019","unstructured":"Schreiber K, Hunt BJ. Managing antiphospholipid syndrome in pregnancy. Thromb Res. 2019;181:S41\u20136.","journal-title":"Thromb Res"},{"key":"1702_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-7-9","volume":"7","author":"K Sperber","year":"2009","unstructured":"Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol. 2009;7:1\u20139.","journal-title":"Pediatr Rheumatol"},{"issue":"6","key":"1702_CR57","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1080\/08923973.2020.1835951","volume":"42","author":"S Sadeghpour","year":"2020","unstructured":"Sadeghpour S, Ghasemnejad Berenji M, Nazarian H, Ghasemnejad T, Nematollahi MH, Abroon S, et al. Effects of treatment with hydroxychloroquine on the modulation of Th17\/Treg ratio and pregnancy outcomes in women with recurrent implantation failure: clinical trial. Immunopharmacol Immunotoxicol. 2020;42(6):632\u201342.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"8","key":"1702_CR58","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1080\/01443615.2022.2141615","volume":"42","author":"A Moini","year":"2022","unstructured":"Moini A, Sepidarkish M, Dehpour AR, Rabiei M, Abiri A, Pirjani R. The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study pilot study. J Obstet Gynaecol. 2022;42(8):3471\u20136.","journal-title":"J Obstet Gynaecol"},{"issue":"2","key":"1702_CR59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.25122\/jml-2022-0095","volume":"16","author":"M Mirzaei","year":"2023","unstructured":"Mirzaei M, Amirajam S, Moghimi ES, Behzadi S, Rohani A, Zerangian N, et al. The effects of hydroxychloroquine on pregnancy outcomes in infertile women: a systematic review and meta-analysis. J Med Life. 2023;16(2):189.","journal-title":"J Med Life"},{"key":"1702_CR60","doi-asserted-by":"publisher","first-page":"1113127","DOI":"10.3389\/fmed.2023.1113127","volume":"10","author":"S Ye","year":"2023","unstructured":"Ye S, Liu Y, Zhao X, Ma Y, Wang Y. Hydroxychloroquine improves pregnancy outcomes of women with positive antinuclear antibody spectrum test results. Front Med. 2023;10:1113127.","journal-title":"Front Med"},{"issue":"1","key":"1702_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bcp.14131","volume":"86","author":"C de Moreuil","year":"2020","unstructured":"de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine May be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol. 2020;86(1):39\u201349.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01702-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01702-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01702-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:02:36Z","timestamp":1748491356000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01702-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01702-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5855263\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the principles outlined in the Declaration of Helsinki. The Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran, approved the study (Ethics Code: IR.TUMS.MEDICINE.REC.1402.699; 2024 March 04). After receiving the necessary information, all participants read and signed the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}